# TH1902 in Patients With Advanced Solid Tumors

> **NCT04706962** · PHASE1 · ACTIVE_NOT_RECRUITING · sponsor: **Theratechnologies** · enrollment: 70 (estimated)

## Conditions studied

- Solid Tumor
- TNBC - Triple-Negative Breast Cancer
- Hormone Receptor-positive Breast Cancer
- Epithelial Ovarian Cancer
- Endometrial Cancer
- Cutaneous Melanoma
- Thyroid Cancer
- Small-cell Lung Cancer
- Prostate Cancer
- SORT1+ Cancers

## Interventions

- **DRUG:** TH1902

## Key facts

- **NCT ID:** NCT04706962
- **Lead sponsor:** Theratechnologies
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2021-03-04
- **Primary completion:** 2025-12
- **Final completion:** 2026-01
- **Target enrollment:** 70 (ESTIMATED)
- **Last updated:** 2025-04-15

## Collaborators

- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04706962

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04706962, "TH1902 in Patients With Advanced Solid Tumors". Retrieved via AI Analytics 2026-07-02 from https://api.ai-analytics.org/clinical/NCT04706962. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*